| Dr Michael Anthony Richardson, MD | |
|
680 Miramonte Dr, Santa Barbara, CA 93109-1429 | |
| (805) 966-5504 | |
| (805) 966-4621 |
| Full Name | Dr Michael Anthony Richardson |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 49 Years |
| Location | 680 Miramonte Dr, Santa Barbara, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124063110 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | A30569 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ventura County Medical Center | Ventura, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| County Of Ventura | 7911810171 | 208 |
News Archive
Members of the public in sub-Saharan Africa who are carriers of the hereditary disease sickle cell disease must be educated aggressively through public health campaigns to raise awareness of the risks of parenting offspring with the disease if their partner is also a carrier, according to research published in the International Journal of Medical Engineering and Informatics.
Yet despite the care the administration took in establishing incentives and safeguards, even some of Obamacare's most committed backers are wondering whether the experiment will work as advertised -; or, like Harvard's P.P.O., go off the rails along the way. Adverse selection is perhaps the direst threat. ... Healthier Americans will probably flock to cheaper bronze plans. And insurers will vie to enroll the healthy. In some states, big insurers have chosen not to participate in exchanges to avoid their strictures. On the outside, they could still sell cheap plans to skim off the healthy and avoid a rule that insurers on the exchanges must also offer more generous silver and gold plans (Eduardo Porter, 8/7).
As any child knows, to answer the question, how many? one must start by adding up individual objects in a group.
Results of two clinical trials reported at the American Society for Clinical Oncology Annual Meeting 2015 show continued promise of immune therapies nivolumab and pembrolizumab against advanced melanomas, specifically in the context of PD1 signaling that some tumors use to avoid immune system attack. Dr. Rene Gonzalez, MD, investigator at the University of Colorado Cancer Center and director of the Melanoma Research Clinics at the CU School of Health, is an author of both studies.
› Verified 3 days ago
| Entity Name | County Of Ventura |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629167457 PECOS PAC ID: 7911810171 Enrollment ID: O20031112000587 |
News Archive
Members of the public in sub-Saharan Africa who are carriers of the hereditary disease sickle cell disease must be educated aggressively through public health campaigns to raise awareness of the risks of parenting offspring with the disease if their partner is also a carrier, according to research published in the International Journal of Medical Engineering and Informatics.
Yet despite the care the administration took in establishing incentives and safeguards, even some of Obamacare's most committed backers are wondering whether the experiment will work as advertised -; or, like Harvard's P.P.O., go off the rails along the way. Adverse selection is perhaps the direst threat. ... Healthier Americans will probably flock to cheaper bronze plans. And insurers will vie to enroll the healthy. In some states, big insurers have chosen not to participate in exchanges to avoid their strictures. On the outside, they could still sell cheap plans to skim off the healthy and avoid a rule that insurers on the exchanges must also offer more generous silver and gold plans (Eduardo Porter, 8/7).
As any child knows, to answer the question, how many? one must start by adding up individual objects in a group.
Results of two clinical trials reported at the American Society for Clinical Oncology Annual Meeting 2015 show continued promise of immune therapies nivolumab and pembrolizumab against advanced melanomas, specifically in the context of PD1 signaling that some tumors use to avoid immune system attack. Dr. Rene Gonzalez, MD, investigator at the University of Colorado Cancer Center and director of the Melanoma Research Clinics at the CU School of Health, is an author of both studies.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Anthony Richardson, MD 680 Miramonte Dr, Santa Barbara, CA 93109-1429 Ph: (805) 966-5504 | Dr Michael Anthony Richardson, MD 680 Miramonte Dr, Santa Barbara, CA 93109-1429 Ph: (805) 966-5504 |
News Archive
Members of the public in sub-Saharan Africa who are carriers of the hereditary disease sickle cell disease must be educated aggressively through public health campaigns to raise awareness of the risks of parenting offspring with the disease if their partner is also a carrier, according to research published in the International Journal of Medical Engineering and Informatics.
Yet despite the care the administration took in establishing incentives and safeguards, even some of Obamacare's most committed backers are wondering whether the experiment will work as advertised -; or, like Harvard's P.P.O., go off the rails along the way. Adverse selection is perhaps the direst threat. ... Healthier Americans will probably flock to cheaper bronze plans. And insurers will vie to enroll the healthy. In some states, big insurers have chosen not to participate in exchanges to avoid their strictures. On the outside, they could still sell cheap plans to skim off the healthy and avoid a rule that insurers on the exchanges must also offer more generous silver and gold plans (Eduardo Porter, 8/7).
As any child knows, to answer the question, how many? one must start by adding up individual objects in a group.
Results of two clinical trials reported at the American Society for Clinical Oncology Annual Meeting 2015 show continued promise of immune therapies nivolumab and pembrolizumab against advanced melanomas, specifically in the context of PD1 signaling that some tumors use to avoid immune system attack. Dr. Rene Gonzalez, MD, investigator at the University of Colorado Cancer Center and director of the Melanoma Research Clinics at the CU School of Health, is an author of both studies.
› Verified 3 days ago
Dr. Emily Graeme Waterhouse, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 400 W Pueblo St, Santa Barbara, CA 93105 Phone: 805-563-8333 | |
Mr. Michael R Repik, D.O. Pathology Medicare: Not Enrolled in Medicare Practice Location: 11 W Figueroa St, Santa Barbara, CA 93101 Phone: 805-419-5667 | |
David G Martin-reay, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: Pueblo At Bath Street, Santa Barbara, CA 93105 Phone: 805-569-7367 Fax: 805-569-8354 | |
Stewart William Comer, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 454 S. Patterson Ave, Pacific Diagnostic Laboratory, Santa Barbara, CA 92111 Phone: 805-569-7582 | |
Dr. Faith Mary Ough, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 400 W Pueblo St, Santa Barbara, CA 93105 Phone: 805-569-7367 | |
Monica Phillips, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 400 W Pueblo St, Santa Barbara, CA 93105 Phone: 805-569-7367 |